Galen announces exclusive licensing agreement with Almeda Pharmaceuticals AG for new Microtabs Plus product.

24 January 2024

Galen announces exclusive licensing agreement with Almeda Pharmaceuticals AG for new Microtabs Plus product.

[Craigavon, Northern Ireland] Galen, the privately-owned pharmaceutical sales and marketing company, is pleased to announce a significant milestone in its global expansion strategy with the signing of an exclusive licensing deal with Almeda Pharmaceuticals AG.

The agreement provides Almeda Pharma with exclusive rights to license Galen’s latest product development PKU EASY Microtabs Plus, across several markets, including Ukraine, Moldova, Georgia, Armenia, Azerbaijan, and Kazakhstan.

Designed specifically for individuals with Phenylketonuria (PKU), Galen’s newest product PKU Easy Microtabs Plus, provides a phenylalanine-free protein substitute, enriched with vitamins, minerals, and the essential and non-essential amino acids, which replaces the requirement for a separate vitamin and minerals supplement.

PKU, a metabolic condition that prevents the breakdown of the amino acid phenylalanine, is a rare disease affecting 1 in 10,000 newborns in Europe.[i] If left untreated or inadequately managed, it can cause severe intellectual disability, epilepsy and behavioural problems.

Following the initial launch in Germany and the Nordics in October, Galen is planning a phased rollout of the product across other territories including the UK and the USA within the next 18 months. This expansion further increases access to more convenient care, ultimately enhancing the quality of life for those affected.

Speaking on the company’s announcement, Galen’s Head of Business Development Johnny McGaughey said: “We are thrilled to have signed a deal with Almeda Pharma for the licensing and distribution of Microtabs Plus in these important territories. This partnership aligns with our vision to make a positive impact on global healthcare by ensuring the availability of our products to a wider population and enhancing patient outcomes through like-minded partners”.

“We believe that everyone should have the right to access appropriate health care. Finding innovative solutions to improve access to medicines and treatments is the biggest challenge for many patients today. Through our commitment and daily efforts, we help people overcome this challenge and help them live longer and be healthier. Today we have made one more step forward in this direction.”, said Ala Tocarciuc, CEO of Almeda Pharmaceuticals AG.

More information on the partnership and Galen’s outlicensing opportunities can be found at www.galen-pharma.com   

#END#

Notes to editors

About Galen Medical Nutrition

As a subsidiary of Galen Limited, Galen Medical Nutrition offer a variety of innovative medical foods, for use in the dietary management of metabolic disorders. Formulas are available for disorders such as Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), and Tyrosinemia (TYR) as well as Urea Cycle Disorders (UCD).

Galen Medical Nutrition is committed to bringing innovation, quality, and customer focus to people with metabolic disorders.

For further information please visit:  www.galenmedicalnutrition.com

About Galen

Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland) and product presence in 25 locations covering each continent across the globe.

With over 50 years’ experience, we have 75+ products across a diverse range of therapy areas.

Galen has recently announced ambitious expansion plans across new territories and therapeutic areas through the acquisition of new company and product portfolios as well as product partnerships.

Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value.

For further information please visit: www.galen-pharma.com

About Almac Group

Galen is a member of the Almac Group. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally.

The Group is wholly owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.

The international company is a privately owned organisation that has grown organically over the past five decades and now employs over 7,000 highly skilled personnel across 18 facilities including Europe, the US and Asia.

For further information please visit www.almacgroup.com.

About Almeda Pharmaceuticals AG

Almeda Pharmaceuticals AG is a pharmaceutical company located in Zug, Switzerland. Our mission is to be sustainable in providing value-added, high quality pharmaceutical products to patients.

We continually consolidate our position as being one of the leading pharmaceutical companies in the selected geographies and a trustable business partner.

We believe that everyone should have the right to access the appropriate healthcare. We help people to live longer and be healthier, by finding innovative solutions to improve access to medicines and therapies.

www.almedapharma.ch

References

[i] van Wegberg, A.M.J. et al. (2017) The complete European guidelines on phenylketonuria: Diagnosis and treatment - orphanet journal of rare diseases, BioMed Central. Available at: https://ojrd.biomedcentral.com/articles/10.1186/s13023-017-0685-2 (Accessed: 16 January 2024).